TTX for chemotherapy-induced neuropathic pain

WEX is planning to file a protocol with the U.S. Food and Drug Administration (FDA) for TTX for chemotherapy-induced neuropathic pain. This is a randomized, double-blind, dose-finding, placebo-controlled, multicenter study of the potential efficacy and safety of TTX in patients with CINP. This Phase 3 study will take place at approximately 40 sites in the United States (US) and Canada with a total of 320 patients planned for enrolled. Currently this is being reviewed by the regulatory authorities in the USA and Canada.

Chemotherapy-induced neuropathic pain

Chemotherapy-induced neuropathic pain is an area of unmet medical need for patients treated with some of the most common cancers. The pain that is associated with chemotherapy is a condition that seriously impacts day-to-day function after therapy. A majority of patients treated with two widely-used classes of chemotherapy – the platinums (such as carboplatin and oxaliplatin) and the taxanes (such as paclitaxel and docetaxel) – experience neuropathic pain that can be debilitating and/or dose-limiting for chemotherapy treatment.